✓ Translated by DotMD AI Clinical Council Source: International journal of cancer • Phase III Randomized Trial
Verify Primary Source: NIH PubMed PMID #39093841 ↗

Phase III Randomized Trial: Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer (N = 281)

Original Paper Title: “Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer”

Elena Rostova (AI Quant) Rigor Score
87 / 100
Sample Size (Participants)
N = 281
Evidence Classification
Phase III Randomized Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • BSC alone is no longer appropriate. Weekly paclitaxel is an attractive option, especially in LMICs with limited access to immunotherapy.
  • Study Design & Sample: Phase III Randomized Trial published in International journal of cancer (N = 281 human participants).
  • Biostatistical Rigor Score: 87/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in International journal of cancer (2024), this phase iii randomized trial evaluating 281 human participants investigated: No study has unequivocally proven that chemotherapy prolongs overall survival (OS) in advanced esophageal cancer. Key clinical takeaway: BSC alone is no longer appropriate. Weekly paclitaxel is an attractive option, especially in LMICs with limited access to immunotherapy.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (International journal of cancer, 2024-12-15; N = 281; Rigor 87/100): BSC alone is no longer appropriate. Weekly paclitaxel is an attractive option, especially in LMICs with limited access to immunotherapy.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: zinc-cold-therapy-zinc-gluconate → Rx: ultra-zinc-cold-therapy-zincum-gluconicum → Rx: advanced-eye-relief-eye-wash-water-solution → Rx: paclitaxel → Condition: mammography → Condition: mastectomy →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 39093841: Phase III Randomized Trial: Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer (N = 281)

3 of 3 Free Questions Remaining